Literature DB >> 11820803

Selection of RNA aptamers to the Alzheimer's disease amyloid peptide.

Francisco Ylera1, Rudi Lurz, Volker A Erdmann, Jens Peter Fürste.   

Abstract

Alzheimer's disease is correlated with the deposition of amyloid peptides in the brain of the patients. The amyloid is thus a major target in the search for novel diagnostic and therapeutic approaches. The present work employs in vitro selection to develop new tools for the study of the Alzheimer's disease. The selection strategy enables the design of specific nucleic acids (aptamers) against virtually any target molecule. High-affinity RNA aptamers against the betaA4(1-40) were isolated from a combinatorial library of approximately 10(15) different molecules. The apparent dissociation constants K(d) of these aptamers are 29-48 nM. The binding of the RNA to the amyloid fibrils was confirmed by electron microscopy. The chemical synthesis of these nucleic acids enables tailor-made modifications. By introduction of specific reporter groups these RNAs can become suitable tools for analytical and diagnostic purposes. Thus, this study may introduce a new approach for diagnosis of the Alzheimer's disease. ©2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11820803     DOI: 10.1006/bbrc.2002.6354

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

1.  Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer's disease.

Authors:  Farid Rahimi; Gal Bitan
Journal:  J Vis Exp       Date:  2010-05-13       Impact factor: 1.355

Review 2.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

3.  Time-dependent DNA condensation induced by amyloid beta-peptide.

Authors:  Haijia Yu; Jinsong Ren; Xiaogang Qu
Journal:  Biophys J       Date:  2006-10-06       Impact factor: 4.033

Review 4.  Aptamers as a novel tool for diagnostics and therapy.

Authors:  Onat Kadioglu; Anna Helena Malczyk; Henry Johannes Greten; Thomas Efferth
Journal:  Invest New Drugs       Date:  2015-02-01       Impact factor: 3.850

5.  Identification of an RNA aptamer binding hTERT-derived peptide and inhibiting telomerase activity in MCF7 cells.

Authors:  Akhil Varshney; Jyoti Bala; Baby Santosh; Ashima Bhaskar; Suresh Kumar; Pramod K Yadava
Journal:  Mol Cell Biochem       Date:  2016-12-21       Impact factor: 3.396

6.  Electrical detection of cancer biomarker using aptamers with nanogap break-junctions.

Authors:  Azhar Ilyas; Waseem Asghar; Peter B Allen; Holli Duhon; Andrew D Ellington; Samir M Iqbal
Journal:  Nanotechnology       Date:  2012-06-18       Impact factor: 3.874

7.  An RNA aptamer with potent affinity for a toxic dimer of amyloid β42 has potential utility for histochemical studies of Alzheimer's disease.

Authors:  Kazuma Murakami; Yayoi Obata; Asa Sekikawa; Haruka Ueda; Naotaka Izuo; Tatsuya Awano; Keiji Takabe; Takahiko Shimizu; Kazuhiro Irie
Journal:  J Biol Chem       Date:  2020-03-02       Impact factor: 5.157

8.  Aptamer antagonists of myelin-derived inhibitors promote axon growth.

Authors:  Yuxuan Wang; Zin Z Khaing; Na Li; Brad Hall; Christine E Schmidt; Andrew D Ellington
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

9.  An improved method for the in vitro evolution of aptamers and applications in protein detection and purification.

Authors:  Michael B Murphy; Shirin T Fuller; Paul M Richardson; Sharon A Doyle
Journal:  Nucleic Acids Res       Date:  2003-09-15       Impact factor: 16.971

10.  RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity.

Authors:  Farid Rahimi; Kazuma Murakami; Jamie L Summers; Chi-Hong B Chen; Gal Bitan
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.